Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis

Objective: to evaluate the efficacy of tocilizumab (TCZ) versus tofacitinib (TOFA) in patients with severe and moderate rheumatoid arthritis (RA) who have not previously received methotrexate (MTX). Material and methods. A systematic search for studies dealing with the evaluation of the efficacy of...

Full description

Saved in:
Bibliographic Details
Main Authors: O. V. Shatalova, V. S. Gorbatenko
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2017-04-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/750
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839574172947185664
author O. V. Shatalova
V. S. Gorbatenko
author_facet O. V. Shatalova
V. S. Gorbatenko
author_sort O. V. Shatalova
collection DOAJ
description Objective: to evaluate the efficacy of tocilizumab (TCZ) versus tofacitinib (TOFA) in patients with severe and moderate rheumatoid arthritis (RA) who have not previously received methotrexate (MTX). Material and methods. A systematic search for studies dealing with the evaluation of the efficacy of TCZ and TOFA was made in accordance with the provisions of the instruction «Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)». Indirect comparison of two Function and ORAL Start randomized clinical trials was done, as described by Н.C. Buchera. The trials were comparable in their design and in the baseline characteristics of patients. The efficiency of pharmacotherapy for early RA was evaluated based on the ACR20/50/70 response rates in MTX-naive patients from three endpoints. Results. The indirect comparison of TOFA and TCZ (A MTX general control) after 52 weeks of treatment in MT-naive patients with severe and moderate RA indicated that the use of TOFA 5 mg twice daily and TCZ 8 mg/kg showed no difference in ACR20, ACR50, and ACR70 response rates. Nevertheless, there was a tendency to the greater efficiency of TOFA (5 mg twice daily) than that of TCZ (8 mg/kg). The indirect comparison of TOFA (10 mg twice daily) and TCZ (8 mg/kg) established that TCZ therapy was associated with the lower response rate for ACR50 (by 37%): the relative risk (RR) was 0.63; 95% confidence interval (CI), 0.44–0.90 and for ACR70 (by 51%): RR, 0.49; 95% CI, 0.29–0.83 as compared with TOFA therapy. Conclusion. The indirect comparisons confirmed that monotherapy with TOFA (10 mg twice daily) produced a more pronounced antiinflammatory effect than that with TCZ in MTX-naive patients with early severe and moderate RA of less than one year's duration. There were no statistically significant differences in ACR response rates between the TOFA (5 mg twice daily) and TCZ (8 mg/kg) groups.
format Article
id doaj-art-c5222bf359004959b51e22fffcb1fef9
institution Matheson Library
issn 1996-7012
2310-158X
language Russian
publishDate 2017-04-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj-art-c5222bf359004959b51e22fffcb1fef92025-08-04T14:00:34ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2017-04-01112252910.14412/1996-7012-2017-2-25-292029Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritisO. V. Shatalova0V. S. Gorbatenko1Volgograd State Medical University, Ministry of Health of Russia, VolgogradVolgograd State Medical University, Ministry of Health of Russia, VolgogradObjective: to evaluate the efficacy of tocilizumab (TCZ) versus tofacitinib (TOFA) in patients with severe and moderate rheumatoid arthritis (RA) who have not previously received methotrexate (MTX). Material and methods. A systematic search for studies dealing with the evaluation of the efficacy of TCZ and TOFA was made in accordance with the provisions of the instruction «Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)». Indirect comparison of two Function and ORAL Start randomized clinical trials was done, as described by Н.C. Buchera. The trials were comparable in their design and in the baseline characteristics of patients. The efficiency of pharmacotherapy for early RA was evaluated based on the ACR20/50/70 response rates in MTX-naive patients from three endpoints. Results. The indirect comparison of TOFA and TCZ (A MTX general control) after 52 weeks of treatment in MT-naive patients with severe and moderate RA indicated that the use of TOFA 5 mg twice daily and TCZ 8 mg/kg showed no difference in ACR20, ACR50, and ACR70 response rates. Nevertheless, there was a tendency to the greater efficiency of TOFA (5 mg twice daily) than that of TCZ (8 mg/kg). The indirect comparison of TOFA (10 mg twice daily) and TCZ (8 mg/kg) established that TCZ therapy was associated with the lower response rate for ACR50 (by 37%): the relative risk (RR) was 0.63; 95% confidence interval (CI), 0.44–0.90 and for ACR70 (by 51%): RR, 0.49; 95% CI, 0.29–0.83 as compared with TOFA therapy. Conclusion. The indirect comparisons confirmed that monotherapy with TOFA (10 mg twice daily) produced a more pronounced antiinflammatory effect than that with TCZ in MTX-naive patients with early severe and moderate RA of less than one year's duration. There were no statistically significant differences in ACR response rates between the TOFA (5 mg twice daily) and TCZ (8 mg/kg) groups.https://mrj.ima-press.net/mrj/article/view/750rheumatoid arthritisindirect comparisonmethotrexatetocilizumabtofacitinib
spellingShingle O. V. Shatalova
V. S. Gorbatenko
Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
Современная ревматология
rheumatoid arthritis
indirect comparison
methotrexate
tocilizumab
tofacitinib
title Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
title_full Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
title_fullStr Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
title_full_unstemmed Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
title_short Comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
title_sort comparison of several alternative uses of targeted antirheumatic drugs in monotherapy for early rheumatoid arthritis
topic rheumatoid arthritis
indirect comparison
methotrexate
tocilizumab
tofacitinib
url https://mrj.ima-press.net/mrj/article/view/750
work_keys_str_mv AT ovshatalova comparisonofseveralalternativeusesoftargetedantirheumaticdrugsinmonotherapyforearlyrheumatoidarthritis
AT vsgorbatenko comparisonofseveralalternativeusesoftargetedantirheumaticdrugsinmonotherapyforearlyrheumatoidarthritis